单位：[1]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Da Dao, Wuhan, P. R. China华中科技大学同济医学院附属同济医院血液内科
Chronic myelomonocytic leukemia (CMML) is a heterogeneous neoplastic hematologic disorder with worse overall survival. Half of CMML have mutations, but case with concomitant mutations of DNA methyltransferase 3A (DNMT3A) and Internal tandem duplications of the juxtamembrane domain of FLT3 (FLT3-ITD) in CMML was not reported before. We reported a 51-year-old man who had CMML with concomitant mutations in DNMT3A and FLT3-ITD.The patient received decitabine and sorafenib combined treatment. In this report, we reviewed DNMT3A mutation and FLT3 mutation, and we reviewed treatment of decitabine and sorafenib. This report is significant. First: This is the first report on CMML with double-mutations of DNMT3A and FLT3-ITD. Second: It shows the importance of targeted drug in combined treatment of CMML.
基金：
National Natural Science
Foundation of China (No 81370658).
第一作者单位：[1]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Da Dao, Wuhan, P. R. China
通讯作者：
通讯机构：[1]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Da Dao, Wuhan, P. R. China[*1]Department of Hematology, Tongji Hospital, Tongji Medical College, Hua Zhong University of Science and Technology, Wu Han, Hubei 430030, China.
推荐引用方式(GB/T 7714)：
Jia Gu,Zhiqiong Wang,Min Xiao,et al.Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib[J].Cancer biology & therapy.2017,(10/12):843-849.doi:10.1080/15384047.2017.1281491.
APA：
Jia Gu,Zhiqiong Wang,Min Xiao,Xia Mao,Li Zhu...&Wei Huang.(2017).Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib.Cancer biology & therapy,,(10/12)
MLA：
Jia Gu,et al."Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib".Cancer biology & therapy ..10/12(2017):843-849
